233 related articles for article (PubMed ID: 27221039)
21. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
[TBL] [Abstract][Full Text] [Related]
22. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
Dimri M; Naramura M; Duan L; Chen J; Ortega-Cava C; Chen G; Goswami R; Fernandes N; Gao Q; Dimri GP; Band V; Band H
Cancer Res; 2007 May; 67(9):4164-72. PubMed ID: 17483327
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Greulich H; Chen TH; Feng W; Jänne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR; Meyerson M
PLoS Med; 2005 Nov; 2(11):e313. PubMed ID: 16187797
[TBL] [Abstract][Full Text] [Related]
24. The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer.
Naudin C; Chevalier C; Roche S
Oncotarget; 2016 Mar; 7(10):11033-55. PubMed ID: 26788993
[TBL] [Abstract][Full Text] [Related]
25. The involvement of oncogenes and suppressor genes in human neoplasia.
Brodeur GM
Adv Pediatr; 1987; 34():1-44. PubMed ID: 3318293
[TBL] [Abstract][Full Text] [Related]
26. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
O'Bryan S; Dong S; Mathis JM; Alahari SK
Eur J Cancer; 2017 Feb; 72():1-11. PubMed ID: 27997852
[TBL] [Abstract][Full Text] [Related]
27. Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.
Grabocka E; Commisso C; Bar-Sagi D
Clin Cancer Res; 2015 Mar; 21(6):1243-7. PubMed ID: 25424849
[TBL] [Abstract][Full Text] [Related]
28. Rho family proteins and Ras transformation: the RHOad less traveled gets congested.
Zohn IM; Campbell SL; Khosravi-Far R; Rossman KL; Der CJ
Oncogene; 1998 Sep; 17(11 Reviews):1415-38. PubMed ID: 9779988
[TBL] [Abstract][Full Text] [Related]
29. [Pituitary tumor-transforming gene, an oncogene implicated in the separation of sister-chromatids and also in the genetic instability of tumors].
Jeanteur P
Bull Cancer; 1999 Oct; 86(10):805. PubMed ID: 10610130
[No Abstract] [Full Text] [Related]
30. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
31. The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models.
Neil JC; Gilroy K; Borland G; Hay J; Terry A; Kilbey A
Adv Exp Med Biol; 2017; 962():247-264. PubMed ID: 28299662
[TBL] [Abstract][Full Text] [Related]
32. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
33. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.
McCubrey JA; Abrams SL; Fitzgerald TL; Cocco L; Martelli AM; Montalto G; Cervello M; Scalisi A; Candido S; Libra M; Steelman LS
Adv Biol Regul; 2015 Jan; 57():75-101. PubMed ID: 25453219
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.
Pollock CB; Shirasawa S; Sasazuki T; Kolch W; Dhillon AS
Cancer Res; 2005 Feb; 65(4):1244-50. PubMed ID: 15735008
[TBL] [Abstract][Full Text] [Related]
35. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes.
Wu CJ; Qian X; O'Rourke DM
DNA Cell Biol; 1999 Oct; 18(10):731-41. PubMed ID: 10541432
[TBL] [Abstract][Full Text] [Related]
36. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms promoting physiological cells progression into tumorigenesis.
Korbut E; Ptak-Belowska A; Brzozowski T
J Physiol Pharmacol; 2012 Dec; 63(6):565-70. PubMed ID: 23388471
[TBL] [Abstract][Full Text] [Related]
38. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.
Vasseur R; Skrypek N; Duchêne B; Renaud F; Martínez-Maqueda D; Vincent A; Porchet N; Van Seuningen I; Jonckheere N
Biochim Biophys Acta; 2015 Dec; 1849(12):1375-84. PubMed ID: 26477488
[TBL] [Abstract][Full Text] [Related]
39. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
40. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
